U.S. RESEARCH ROUNDUP-GE Healthcare, Summit Materials, Tapestry

Reuters01-08
U.S. RESEARCH ROUNDUP-GE Healthcare, Summit Materials, Tapestry

Jan 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including GE Healthcare, Summit Materials and Tapestry, on Wednesday.

HIGHLIGHTS

* GE Healthcare GEHC.O: Jefferies raises to buy from hold

* Philip Morris International Inc. PM.N: Barclays cuts target price to $145 from $155

* Regeneron Pharmaceuticals Inc REGN.O: Truist Securities cuts PT to $1004 from $1126

* Summit Materials Inc SUM.N: Stephens cuts to equal weight from overweight

* Tapestry Inc TPR.N: Barclays raises to overweight from equal weight

Following is a summary of research actions on U.S. companies reported by Reuters on Wednesday. Stock entries are in alphabetical order.

* Abbvie ABBV.N: Truist Securities cuts target price to $211 from $215

* Affirm Holdings Inc AFRM.O: RBC raises target price to $67 from $52

* Amgen Inc AMGN.O: Truist Securities cuts target price to $298 from $333

* Biogen BIIB.O: Truist Securities cuts target price to $220 from $302

* Bristol-Myers Squibb Co BMY.N: Truist Securities raises PT to $65 from $62

* Constellation Energy Corp CEG.O: JP Morgan raises target price to $348 from $342

* Enact Holdings Inc ACT.O: KBW cuts target price to $41 from $43

* Fidelity National Financial Inc FNF.N: KBW cuts target price to $63 from $64

* First American Financial Corp FAF.N: KBW cuts target price to $74 from $80

* GE Healthcare GEHC.O: Jefferies raises target price to $103 from $95

* GE Healthcare GEHC.O: Jefferies raises to buy from hold

* Getty Realty Corp GTY.N: RBC cuts target price to $32 from $33

* Inari Medical Inc NARI.O: Jefferies cuts to hold from buy

* Inari Medical Inc NARI.O: Jefferies raises target price to $80 from $70

* Levi Strauss & Co LEVI.N: Barclays initiates coverage with overweight rating; PT $24

* Lindsay Corp LNN.N: Stifel raises target price to $130 from $126

* Merck & Co Inc MRK.N: Truist Securities cuts target price to $110 from $130

* Merck & Co Inc MRK.N: Truist Securities cuts to hold from buy

* Meritage Homes Corp MTH.N: KBW cuts target price to $97 from $194

* Mgic Investment Corp MTG.N: KBW cuts target price to $28 from $29

* Nektar Therapeutics NKTR.O: B. Riley initiates coverage with buy rating; PT $4

* Nextera Energy Partners LP NEP.N: CIBC cuts target price to $21 from $26

* Nike Inc NKE.N: RBC cuts target price to $70 from $80

* NMI Holdings Inc NMIH.O: KBW cuts target price to $43 from $44

* Philip Morris International Inc. PM.N: Barclays cuts target price to $145 from $155

* Phreesia Inc PHR.N: RBC raises to outperform from sector perform; ups PT to $32 from $24

* Radian Group Inc RDN.N: KBW cuts target price to $40 from $41

* Regeneron Pharmaceuticals Inc REGN.O: Truist Securities cuts PT to $1004 from $1126

* RPM International Inc RPM.N: JP Morgan cuts target price to $124 from $126

* Stewart Information Services Corp STC.N: KBW cuts target price to $74 from $84

* Summit Materials Inc SUM.N: Stephens cuts target price to $52.50 from $56

* Summit Materials Inc SUM.N: Stephens cuts to equal weight from overweight

* Talen Energy Corp TLN.O: JP Morgan raises target price to $288 from $268

* Tapestry Inc TPR.N: Barclays raises target price to $87 from $57

* Tapestry Inc TPR.N: Barclays raises to overweight from equal weight

* Vistra Corp VST.N: JP Morgan raises target price to $180 from $178

(Compiled by Bengaluru Newsroom)

((Diaries@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment